Companies: 49,246 Total Market Cap: 132441797263938.02

Basilea Pharmaceutica AG

SWX-BSLN
Healthcare Biotechnology
Rank #11833
Market Cap 655.77 M
Volume 34,920
Price 53.75
Change (%) 0.56%
Country or region Switzerland Switzerland

Basilea Pharmaceutica AG's latest marketcap:

655.77 M

As of 05/20/2025, Basilea Pharmaceutica AG's market capitalization has reached $655.77 M. According to our data, Basilea Pharmaceutica AG is the 11833th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 655.77 M
Revenue (ttm) 250.50 M
Net Income (ttm) 93.20 M
Shares Out 12.27 M
EPS (ttm) 7
Forward PE 11.01
Ex-Dividend Date n/a
Earnings Date 08/19/2025
Market Cap Chart
Data Updated: 05/20/2025

Basilea Pharmaceutica AG's yearly market capitalization.

Basilea Pharmaceutica AG has seen its market value drop from ₣574.19 M to ₣545.93 M since 2020, representing a total decrease of 4.92% and an annual compound decline rate (CAGR) of 1.14%.
Date Market Cap Change (%)
05/20/2025 ₣545.93 M 7.46%
12/30/2024 ₣501.21 M 18.52%
12/29/2023 ₣422.90 M -22.52%
12/30/2022 ₣545.84 M 12.62%
12/30/2021 ₣484.67 M -15.59%
12/30/2020 ₣574.19 M

Company Profile

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for bacterial and fungal infections. Headquartered in Allschwil, Switzerland, the company was established in 2000.

Key Products & Pipeline

  • Cresemba: An intravenous antifungal medication used to treat invasive aspergillosis and mucormycosis.
  • Fosmanogepix: Currently in Phase II clinical trials, this antifungal drug targets Candidemia.
  • BAL2062: A treatment for invasive mold infections, now in Phase I clinical trials.
  • BAL2420: An antibiotic under development for severe Enterobacteriaceae infections.
  • Zevtera: An antibiotic approved for pneumonia treatment, with ongoing development for Staphylococcus aureus bacteremia and acute bacterial skin infections.

Basilea Pharmaceutica AG remains committed to advancing innovative therapies to address critical infectious diseases worldwide.

Frequently Asked Questions

As of 05/20/2025, Basilea Pharmaceutica AG (including the parent company, if applicable) has an estimated market capitalization of $655.77 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Basilea Pharmaceutica AG global market capitalization ranking is approximately 11833 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Switzerland
Founded 2000
IPO Date n/a
Employees 164
CEO David Veitch
Sector Healthcare
Industry Biotechnology
Address Hegenheimermattweg 167b
Allschwil, 4123
Switzerland
Website https://www.basilea.com
People Also Watch
VRTX
444.31 0.64%
CSL Limited
156.27 0.64%
REGN
605.54 0.64%
KRX-207940
731.22 0.64%